US3174899A - Composition for the management of post antibiotic enteritis - Google Patents
Composition for the management of post antibiotic enteritis Download PDFInfo
- Publication number
- US3174899A US3174899A US79583A US7958360A US3174899A US 3174899 A US3174899 A US 3174899A US 79583 A US79583 A US 79583A US 7958360 A US7958360 A US 7958360A US 3174899 A US3174899 A US 3174899A
- Authority
- US
- United States
- Prior art keywords
- grams
- hydroxy
- phenanthroline
- quinone
- iodoquinoline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title description 54
- 230000001374 post-anti-biotic effect Effects 0.000 title description 6
- 208000004232 Enteritis Diseases 0.000 title description 5
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 29
- 239000003937 drug carrier Substances 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims description 17
- 229930182555 Penicillin Natural products 0.000 claims description 16
- 239000004098 Tetracycline Substances 0.000 claims description 15
- 229940049954 penicillin Drugs 0.000 claims description 15
- 235000019364 tetracycline Nutrition 0.000 claims description 15
- 150000003522 tetracyclines Chemical class 0.000 claims description 15
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 claims description 14
- 239000003242 anti bacterial agent Substances 0.000 claims description 14
- 230000003115 biocidal effect Effects 0.000 claims description 14
- 229960003276 erythromycin Drugs 0.000 claims description 14
- 229960002180 tetracycline Drugs 0.000 claims description 13
- 229930101283 tetracycline Natural products 0.000 claims description 13
- 229930193140 Neomycin Natural products 0.000 claims description 11
- 229930027917 kanamycin Natural products 0.000 claims description 10
- 229960000318 kanamycin Drugs 0.000 claims description 10
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 10
- 229930182823 kanamycin A Natural products 0.000 claims description 10
- 229960004927 neomycin Drugs 0.000 claims description 10
- ACTOXUHEUCPTEW-BWHGAVFKSA-N 2-[(4r,5s,6s,7r,9r,10r,11e,13e,16r)-6-[(2s,3r,4r,5s,6r)-5-[(2s,4r,5s,6s)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-10-[(2s,5s,6r)-5-(dimethylamino)-6-methyloxan-2-yl]oxy-4-hydroxy-5-methoxy-9,16-dimethyl-2-o Chemical compound O([C@H]1/C=C/C=C/C[C@@H](C)OC(=O)C[C@@H](O)[C@@H]([C@H]([C@@H](CC=O)C[C@H]1C)O[C@H]1[C@@H]([C@H]([C@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(O)C2)[C@@H](C)O1)N(C)C)O)OC)[C@@H]1CC[C@H](N(C)C)[C@@H](C)O1 ACTOXUHEUCPTEW-BWHGAVFKSA-N 0.000 claims description 8
- 108010001478 Bacitracin Proteins 0.000 claims description 8
- -1 CHLORAMPHEICOL Natural products 0.000 claims description 8
- 229930188120 Carbomycin Natural products 0.000 claims description 8
- DYDCUQKUCUHJBH-UWTATZPHSA-N D-Cycloserine Chemical compound N[C@@H]1CONC1=O DYDCUQKUCUHJBH-UWTATZPHSA-N 0.000 claims description 8
- DYDCUQKUCUHJBH-UHFFFAOYSA-N D-Cycloserine Natural products NC1CONC1=O DYDCUQKUCUHJBH-UHFFFAOYSA-N 0.000 claims description 8
- 239000004187 Spiramycin Substances 0.000 claims description 8
- FQVHOULQCKDUCY-OGHXVOSASA-N [(2s,3s,4r,6s)-6-[(2r,3s,4r,5r,6s)-6-[[(1s,3r,7r,8s,9s,10r,12r,14e,16s)-7-acetyloxy-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy]-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2,4-dimeth Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@H]1[C@@H](CC=O)C[C@@H](C)C(=O)/C=C/[C@@H]2O[C@H]2C[C@@H](C)OC(=O)C[C@H]([C@@H]1OC)OC(C)=O)[C@H]1C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O1 FQVHOULQCKDUCY-OGHXVOSASA-N 0.000 claims description 8
- 229960003071 bacitracin Drugs 0.000 claims description 8
- 229930184125 bacitracin Natural products 0.000 claims description 8
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 claims description 8
- 229950005779 carbomycin Drugs 0.000 claims description 8
- 229960003077 cycloserine Drugs 0.000 claims description 8
- 229960001294 spiramycin Drugs 0.000 claims description 8
- 229930191512 spiramycin Natural products 0.000 claims description 8
- 235000019372 spiramycin Nutrition 0.000 claims description 8
- 235000019367 oleandomycin Nutrition 0.000 claims description 7
- RZPAKFUAFGMUPI-UHFFFAOYSA-N Oleandomycin Natural products O1C(C)C(O)C(OC)CC1OC1C(C)C(=O)OC(C)C(C)C(O)C(C)C(=O)C2(OC2)CC(C)C(OC2C(C(CC(C)O2)N(C)C)O)C1C RZPAKFUAFGMUPI-UHFFFAOYSA-N 0.000 claims description 6
- 239000004104 Oleandomycin Substances 0.000 claims description 6
- 229960002351 oleandomycin Drugs 0.000 claims description 6
- RZPAKFUAFGMUPI-KGIGTXTPSA-N oleandomycin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@]2(OC2)C[C@H](C)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C RZPAKFUAFGMUPI-KGIGTXTPSA-N 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 description 26
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 24
- 229940100445 wheat starch Drugs 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 16
- 239000008101 lactose Substances 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 235000019359 magnesium stearate Nutrition 0.000 description 12
- 235000012054 meals Nutrition 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 240000008042 Zea mays Species 0.000 description 9
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 9
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 9
- 235000005822 corn Nutrition 0.000 description 9
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- ISWNAMNOYHCTSB-UHFFFAOYSA-N methanamine;hydrobromide Chemical compound [Br-].[NH3+]C ISWNAMNOYHCTSB-UHFFFAOYSA-N 0.000 description 8
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- JJCWKVUUIFLXNZ-UHFFFAOYSA-M 2-hydroxyethyl(trimethyl)azanium;bromide Chemical compound [Br-].C[N+](C)(C)CCO JJCWKVUUIFLXNZ-UHFFFAOYSA-M 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 238000009835 boiling Methods 0.000 description 5
- 229960005091 chloramphenicol Drugs 0.000 description 5
- 239000011363 dried mixture Substances 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000005469 granulation Methods 0.000 description 5
- 230000003179 granulation Effects 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 244000075850 Avena orientalis Species 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 235000007319 Avena orientalis Nutrition 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 3
- 235000019733 Fish meal Nutrition 0.000 description 3
- 108010068370 Glutens Proteins 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- 240000004658 Medicago sativa Species 0.000 description 3
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 235000019764 Soybean Meal Nutrition 0.000 description 3
- 229930003270 Vitamin B Natural products 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 229960004475 chlortetracycline Drugs 0.000 description 3
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 150000002148 esters Chemical group 0.000 description 3
- 239000004467 fishmeal Substances 0.000 description 3
- 235000021312 gluten Nutrition 0.000 description 3
- 229940099596 manganese sulfate Drugs 0.000 description 3
- 239000011702 manganese sulphate Substances 0.000 description 3
- 235000007079 manganese sulphate Nutrition 0.000 description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 235000019192 riboflavin Nutrition 0.000 description 3
- 229960002477 riboflavin Drugs 0.000 description 3
- 239000002151 riboflavin Substances 0.000 description 3
- 239000004455 soybean meal Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000019155 vitamin A Nutrition 0.000 description 3
- 239000011719 vitamin A Substances 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- WOAHJDHKFWSLKE-UHFFFAOYSA-N 1,2-benzoquinone Chemical compound O=C1C=CC=CC1=O WOAHJDHKFWSLKE-UHFFFAOYSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 240000007124 Brassica oleracea Species 0.000 description 2
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 235000019752 Wheat Middilings Nutrition 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000020786 mineral supplement Nutrition 0.000 description 2
- 229940029985 mineral supplement Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229940040944 tetracyclines Drugs 0.000 description 2
- AMZJKFHHVQNUPT-JFGNBEQYSA-N (2s,5r,6r)-6-[(2-butylsulfanylacetyl)amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound S1C(C)(C)[C@H](C(O)=O)N2C(=O)[C@@H](NC(=O)CSCCCC)[C@H]21 AMZJKFHHVQNUPT-JFGNBEQYSA-N 0.000 description 1
- ADIHZDIWDRJIOQ-JFGNBEQYSA-N (2s,5r,6r)-6-[[2-(3-chlorobut-2-enylsulfanyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound S1C(C)(C)[C@H](C(O)=O)N2C(=O)[C@@H](NC(=O)CSCC=C(Cl)C)[C@H]21 ADIHZDIWDRJIOQ-JFGNBEQYSA-N 0.000 description 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 241000219793 Trifolium Species 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 229940036811 bone meal Drugs 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- PNNKWTMBTSKGJR-UHFFFAOYSA-M diethyl-(2-hydroxyethyl)-methylazanium;bromide Chemical compound [Br-].CC[N+](C)(CC)CCO PNNKWTMBTSKGJR-UHFFFAOYSA-M 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- AZQWKYJCGOJGHM-UHFFFAOYSA-N para-benzoquinone Natural products O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- NONJJLVGHLVQQM-JHXYUMNGSA-N phenethicillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C(C)OC1=CC=CC=C1 NONJJLVGHLVQQM-JHXYUMNGSA-N 0.000 description 1
- 229960004894 pheneticillin Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 229960003147 reserpine Drugs 0.000 description 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000015099 wheat brans Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
- A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
Definitions
- Example 5 Grams 4:7-phenanthroline-5:6-quinone 200.0 S-chloro-8-hydroxy-7-iodoquinoline 2000.0 Dimethyl Z-hydroxyethyl methylarnmonium bromide a-phenyl-cyclohexaneglycolate 20.0 Chlortetracycline HCl, powder 2500.0 Lactose 3280.0
- a pharmaceutical composition comprising about 1-5 mg. 4:7-phenanthroline-5:6-quinone, about 1-2 mg. dimethyl (Z-hydroxyethyl)methylammonium bromide uphenyl-cyclohexaneglycolate and an effective amount of an antibiotic selected from the group consisting of a penicillin, a tetracycline, bactitracin, carbornycin, cycloserine, erythromycin, chloramphenicol, kanamycin, neomycin, oleandomycin, spiramycin per 10-6 mg. 5-chloro-8-hydroxy-7-iodoquinoline, and an inert pharmaceutical carrier.
- an antibiotic selected from the group consisting of a penicillin, a tetracycline, bactitracin, carbornycin, cycloserine, erythromycin, chloramphenicol, kanamycin, neomycin, oleandomycin, spiramycin
- a pharmaceutical composition comprising about 1-5 mg. 4:7-phenanthroline-5:6-quinone, about 1-2 mg.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Description
3,174,899 COMPOSITEON FOR THE MANAGEMENT OF POST ANTIBIOTIC ENTERTTIS Anthony E. Ahramo, Short Hills, and Philip Carl Eisman, Morris Plains, NJ, assignors to Cilia Corporation, a corporation of Delaware N Drawing. Filed Dec. 30, 1960, Ser. No. 79,583 19 Claims. (Cl. 16753) This invention relates to and has for its object the provision of novel compositions (and methods for their preparation), useful for the treatment and/or prevention of infections involving post antibiotic enteritis, such as intestinal moniliasis, caused by species of Candida, usually C. albicaizs, or other diarrheas, such as those caused by B. roteus and Enterococcus species, etc. These compositions are made containing (1) an antibiotic, (2) a member selected from the group consisting of 1:7- and 4:7-phenanthroline-5 6-quinones (particularly 4 :7-phenanthroline-S:6-quinones, especially 4:7-phen2nithroline- .5z6-quinone) and (3) -chloro-8-hydroXy-7-iodoquinoline. An equivalent intestinal antiseptic may be used in place of the S-chloro-8-hydroxy-7-iodoquinoline and a spasmolytic agent, such as diethyl (2-hydroxyethyl)methylammonium bromide a-phenyl-cyclohexaneglycolate or an equivalent compound may be added.
One of the difiicnlties which is often encountered as a result of the prolonged administration of antibiotics is alteration of the intestinal flora and resultant secondary infection. This may also occur from administration of the antibiotic even when repeated use is not necessary. One of the common infections resulting from antibiotic administration is intestinal moniliasis. This condition, evidenced by the increased number of intestinal yeasts, is highly susceptible to treatment with the compositions of the invention, as are diarrheas caused by other microorganisms, which may act as secondary invaders, as indicated above.
The antibiotics used in the invention are those having antibacterial, not antifungal, effect and include, inter alia, penicillin in any of its therapeutically effective forms, such as penicillin, penicillin AT, penicillin BT, penicillin G, penicillin SP, penicillin S, pencillin V, phenethicillin, etc., the tetracyclines, such as tetracycline, chlortetracycline, oxytetracycline, desmethylchlortetracycline, bacitracin, carbomycin, cycloserine, erythromycin, chloramphenicol, kanamycin, neomycin, oleandomycin, spiramycin, etc. Many of these antibiotics are utilized in acidaddition salt or ester form and the invention includes the use of these salts or esters. Most of these forms are described in New and Nonofficial Drugs, Lippincott Co., Philadelphia, Pa., 1960, pages 70-142, which disclosure is inocrporated herein by reference with respect to oral antibacterial antibiotics. The phenanthroline-S:6-quinones which may be used include those covered in US. Patent No. 2,706,197 or equivalent compounds.
In the compositions of the invention the proportions may vary and one may have, per 10-6 mg. S-chloro-S-hydroxy-7-iodoquinoline, the daily dosage of antibiotic plus 1-5 mg. 4:7-phenanthroline-5:6-quinone and, if desired, 12 mg. dimethyl(Z-hydroxyethyl)methylammonium bromide a-phenyl-cyclohexaneglycolate. The daily dosages of the antibitoics are, of course, known. Thus, the penicillins may be administered daily as 11.5 million units;
States Patent the tetracyclines as 1-1.5 grams; the erythromycins as 11.5 grams; the chloramphenicols as 1-1.5 grams; the neomycins as l-1.5 grams; kanamycin as 3-4 grams; cycloserine as .25.50 gram; bacitracin as 80,000120,000 units; carbomycin as 1-2 grams; the oleandomycins as 1-2 grams; etc.
For making up the preparations of the invention there can be employed substances which do not react with the neW compounds, such as gelatine, lactose, starches, stearic acid, magnesium stearate, stearyl alcohol, talc, vegetable oils, benzyl alcohols, gums, propylene glycol, polyaykylene glycols or any other known carrier for medicaments. The pharmaceutical preparations may be in the solid form, for example, as capsules, tablets or dragees, or in liquid form, for example, as suspensions or emulsions. If desired, they may contain auxiliary substances, such as preserving agents, stabilizing agents, wetting or emulsifying agents. They may also contain, in combination, other therapeutically useful substances. The dose level at which these compounds are used may vary considerably depending upon the condition of the patient, but the desirable dosage may be easily determined by the practicing physician.
The compositions of the invention may also be incorporated in feeds or administered in any other standard way for animal use. When incorporated in feeds, the feed compositions may contain the usual feed components, such as grains, protein supplements, mineral supplements, grain feed vitamin supplements, and other supplements in ratios and proportions known to be best adaptable to the particular bird or animal being fed. Examples of suitable feed constituents include barley, barley meal, buckwheat, corn, cornmeal, kafir, oats, oat groats, ground oats, rolled oats, rye, wheat, wheat bran, wheat shorts, wheat middlings, milk, bone meal, meat scrap, corn gluten meal, oil cake meal, soybean meal, fish meal, alfalfa, dehydrated alfalfa meal, clover, lawn clippings, cabbage, kale, cod liver oil, and similar nutrients, as well as mineral supplements, such as di-caleium phosphate, calcium carbonate, iodized salt, manganese sulfate and the like, vitamins, e.g., vitamin A, niacin, calcium, pantothenate, thiamine, riboflavin, vitamin B ascorbic acid, vitamin D and the like, other essential supplements, e.g., butylated hydroxy-toluene, methionine and the like, as Well as other growth stimulants, such as reserpine or derivatives thereof, e.g., esters or ethers of compounds having the basic reserpine structure.
For veterinary use, it may be preferable to prepare a composition of the invention, together with a suitable blender, e.g., wheat middlings or any other suitable blender. The medicated feed is prepared according to standard procedures by adding the premix in amounts to make up the desired concentration of the active compound in the final medicated feed. A premix contains from about 0.1 to about 20 percent, more especially from 0.5 to about 10 percent of the inventive composition, together with a suitable blender. The content of the pharmacologically active ingredients may depend on the type of treatment intended, e.g., short term or prolonged medication. With respect to the therapeutic composition, the feed materials obviously represent an inert pharmaceutical carrier.
An animal feed, containing the composition of Example a 5, infra (Therapeutic Composition A), may be prepared as follows. Premix: G. Therapeutic Composition A 800.000 Wheat standard middlings, 30-80 mesh 10,200.00
Total weight 11,000.000
Feed formula:
Corn meal 1,062.875 Fat 80.000 Fish meal, 60% protein 100.000 Soybean meal, 50% protein 500.000 Corn gluten meal 100.000 Dehydrated alfalfa meal 50.000 Corn distiller solubles 40.000 Di-calcium phosphate 28.000 Calcium carbonate 20.000
Iodized salt 10.000 Vitamins A and D (1,000,000 A and 250,-
000 D/pound 4.000 Calcium pantothenate 0.250 Butylated hydroxy toluene 0.250 Choline chloride, 25% 2.500 Riboflavin conc. (24 g. per pound) 0.125 Vitamin B (0.02 g. per pound) 1.000 Methionine 0.500 Manganese sulfate 0.500
Total Weight 2,000.000
The premix is made by adding Therapeutic Composition A to the Wheat and then mixing until uniformity is obtained.
The feed formula is prepared as follows: A portion of the corn meal is introduced into the blending machine (about half of the amount to be added). The remaining corn meal, previously blended with the preheated, liquified fat, is added thereto and mixing is continued until uniformity is obtained. The manganese sulfate, di-calcium phosphate, calcium carbonate and iodized salt are then added with mixing, followed by the addition of the fish meal, soy bean meal, corn gluten meal and corn distiller solubles. After a uniform mixture has been obtained, vitamins A and D, calcium pantothenate, choline chloride, riboflavin, vitamin B and methionine are added in that order. Mixing is continued after the addition of butylated hydroxy toluene, and maintained until a uniform product is obtained.
The premix is added to the feed formula prepared as described above.
Following are specific working examples, showing procedures which may be used for preparing the compositions of the invention. It is to be understood that these procedures are merely illustrative and are in no way intended to limit the invention. Throughout the specification and claims, where parts or proportions or percentages are designated, they are always parts, proportions or percentages by Weight, unless otherwise specified. Sieve sizes are US. Standard sieve sizes.
Pr0cedure.Pass (1) the dimethyl(2-hydroxyethyl) methylammonium bromide a-phenyl-cyclohexaneglycolate and the 4:7-phenanthroline-5 :6-quinone through a No. sieve, then mix thoroughly until uniformity has been attained, with a mixture of (2) S-chloro-8-hydroxy-7-iodo quinoline and lactose which has been passed through a No. 20 sieve. Suspend gm. wheat starch in ml. water, then add 150 ml. boiling Water to the starch suspension, and add this suspension to the combined active ingredient mixtures (1) and (2) and granulate. Add ml. of 50% aqueous 3A alcohol to the granulation and mix until uniformity is attained, then pass the resulting mixture through a No. 8 "sieve and dry at 100 F. Pass the resulting dried mixture through a No. 14 sieve and add 150 gm. wheat starch and magnesium stearate. Mix well and compress into 150 mg. core units, using standard concave punches on the Manesty Drycota machine.
Coating: 650 mg.-15/32 650 mg 10,000 Tablets 5-0hloro-8-hydroxy-7-iodoquinoline. 170.0 mg 1,700.0 grams. Lactose 180.0 mg 1,800.0 grams. Wheat Starch 48.0 mg 480.0 grams. Magnesium Stearate 2.0 mg 20.0 grams. Chlortetracycline HCl, powder- 250.0 mg 2,500.0 grams. 3A Alcohol q.s q.s.
Purified Water q.s q.s.
Example 2 Core: 150 mg.10/32 mg.
10,000 Tablets Dimethyl (2hydroxyethyl) methylammonium bromide wphenyl-cyclohexaneglycolate.
4:7 Fhenanthroline-5:ti-quinone 5-0hloro-8-hydroxy-7-iodoquinollne.
Wheat Starch Y 20.0 grams.
100.0 grams. 300.0 grams. 1950 grams.
Lactose 777.0 grams. Magnesium Steara 8.0 grams 3A Alcohol q.s. Purified Water q.s.
Pr0c'edure.-Pass (l) the dimethyl(2 hydroxyethyl)- methylammoniurn bromide a-phenyl-cyclohexaneglycolate and the 4:7 phenanthroline-S:6-quinone through a No. 30 sieve, then mix thoroughly until uniformity has been attained, with a mixture of (2) 5-chloro-8-hydroxy-7 iodoquinoline and lactose which has been passed through: a No. 20 sieve. Suspend 45 gm. wheat starch in 50 ml. Water, then add ml. boiling water to the starch sus-' pension, then add this suspension to the combined active ingredient mixtures (l) and (2) and granulate. Add 120 m1. of 50% aqueous 3A alcohol to the granulation and mix until uniformity is attained, then pass the resulting mixture through a No. 8 sieve and dry at 100 F. Pass the resulting dried mixture through a No. 14 sieve and add 15 gm. Wheat starch and magnesium stearate. Mix Well and compress into 150 mg. core, using standard concave punches on the Mancsty Drycota machine.
Coating: 600 mg.15/32 600 mg. 10,000 Tablets 5-Chloro-8-hydroxy-7-iodoquinoline 120.0 mg 1,200.0 grams. Lactose. 180.0 m" 1,800.0 grams.
Wheat Starch Magnesium Stearate Chlortetraeyeline H01, powde 3A Alcohol Purified Water 480.0 grams.
20.0 grams. 2,500.0 grams. q.s.
Example 3 Core: 150 mg.l/32 I 150 mg. I 10,000 Tablets 4:7-Phenanthroline-5:6-quinoue 20.0 mg 200.0 grains.
3000 grams. 195.0 grams. 709.0 grams. 6.0 grams. 150.0 grams. q.s.
5-Ohloro-8l1ydroxy-7-iodoquinoliua. Wheat Starch Laetose Magnesium Stearate- Wheat Starch 3A Alcohol Procedure.Pass (1) the 4:7-phenanthroline-5:6-quinone through a No. 30 sieve, then pass (2) the S-cholro- 8-hydroxy-7-iodoquinoline and lactose through a No. 20 sieve and mix thoroughly until uniformity is attained. Suspend 45 gm. wheat starch in 50 ml. water, then add 150 ml. boiling water to the starch suspension, then add this suspension to the combined active ingerdient mixtures 1) and (2) and granulate. Add 120 ml. of 50% aqueous 3A alcohol to the granulation and mix until uniformity is attained, then pass the resulting mixture through a No. 8 sieve, and dry at 100 F. Pass the resulting dried mixture through a No. 14 sieve and add 15 gm. wheat starch and magnesium stearate. Mix well and compress into 150 core, using %2" standard concave punches on the Manesty Drycota machine.
Coating: 65:0 Ing.15/32 650 mg. 10,000 Tablets 5-Ghloro-8-hydroxy- -idoquinolin' Lactose Wheat Starch 1,700.0 grams. 1.8000 grams. 480.0 grams.
Magnesium stearate 20.0 grams. Chlortetracyeline I-ICl, powder. 2,500.0 rams. 3A Alcohol q.s.
Purified Water q.s
Core: 150 mg.10/32 150 mg. 10,000 Tablets 4:7-Plicnanthroline-5:fi quiucne. 5-Chloro-S-hydro zy-7-iodoquinolir Wheat Starch 100.0 grams. 300.0 gran s. 195.0 grams.
Lactose 772.0 grams. Magnesium stearate 8.0 grams. 3A Alcohol q.s.
Purified Water q.s.
Pr0cedure.Pass (l) the 4:7-phenanthroline through a No. 30 sieve, then mix thoroughly until uniformity has been attained, with a mixture of (2) S-ehloro-S-hydroxy- 7-iodoquinoline and lactose which has been passed through a No. 20 sieve. Suspend 45 gm. wheat starch in 50 ml. water, then add 150 ml. boiling water to the starch suspension, then add this suspension to the combined active ingredient mixtures (1) and (2) and granulate. Add ml. of 50% aqueous 3A alcohol to the granulation and mix until uniformity is attained, then pass the resulting mixture through a No. 8 sieve and dry at 100 F. Pass the resulting dried mixture through a No. 14 sieve and add 15 gm. wheat starch and magnesium stearate. Mix well and compress into mg. core, using %2 standard concave punches on the Manesty Drycota machine.
Coating: 600 Ing.15/32 10,000 Tablets 1,200.0 grams.
5-Ghl0ro-8-l1ydroxy-7-iod0quiu0line 2,000.0 grams.
Wheat Starch 480.0 grams. Magnesium Stearate 20.0 grams. Chlortetraeyclinc l-ICl, powder. 2,500.0 grams. 3A Alcohol q.s.
Purified Water q.s.
Example 5 Grams 4:7-phenanthroline-5:6-quinone 200.0 S-chloro-8-hydroxy-7-iodoquinoline 2000.0 Dimethyl Z-hydroxyethyl methylarnmonium bromide a-phenyl-cyclohexaneglycolate 20.0 Chlortetracycline HCl, powder 2500.0 Lactose 3280.0
Total 8000.0
Pr0cedure.Fass the ingredients through a No. 20 sieve and mix until uniformity is attained. The resulting mixture (Therapeutic Composition A) may be used as a powder for encapsulation or used as such for inclusion in animal feed compositions in the desired amount.
Example 6 Grams 4:7-phenanthroline-5:S-quinone 200.0 5-chl0r0-8-hydroxy-7-iodoquinoline 2000.0 Neomycin 2500.0 Lactose 3300.0
Total 8000.0
Pn0cedm-e.-Pass the ingredients through a No. 20 sieve and mix until uniformity is attained. The resulting mixture (Therapeutic Composition B) may be used as a powder for encapsulation or used as such for inclusion in animal feed compositions in the desired amount.
Example 7 Grams 4:7-phenanthroline-5:6-quinone 200.0 S-chloro-8-hydroxy-7-iodoquinoline 2000.0 Erythromycin 2500.0 Wheat starch 675.0
Lactose 2600.0
Magnesium stearate 25.0 3A alcohol q.s. Purified water q.s.
Prcedure.Pass (1) the 4:7-phenanthroline-5:6-quinone and 1000 grams lactose through a No. 30 sieve, then mix thoroughly until uniformity has been attained, with a mixture of (2) -Chloro-8-hydr0Xy-7-iodoquin0- line, erythromycin, 275 grams Wheat starch and 1600 grams lactose Which has been passed through a No. 20 sieve. Suspend 100 grams wheat starch in 100 ml. Water, then add 300 ml. boiling water to the starch suspension, and add this suspension to the combined active ingredient mixtures 1) and (2) and granulate after adding 1 liter of 70% aqueous 3A alcohol solution. Add 100 mi. of 50% aqueous 3A alcohol to the granulation and mix until uniformity is attained, then pass the resulting mixture through a No. 8 sieve and dry at 100 F. Pass the resulting dried mixture through a No. 16 sieve, then add the magnesium stearate, the remaining Wheat starch and mix until uniformity is attained. Compress into 850 mg. tablets using concave punches of the desired size on the Manesty Drycota machine. [By substituting 20 grams dimethyl(Z-hydroxyethyl)methylammonium bromide 06- phenyl-cyclohexaneglycolate for 20 grams lactose in preparing mixture 1) above, modified tablets may be made] In the examples given above, one may obviously substitute any equivalent antibiotic in equivalent amount for the antibiotic shown in the examples. The amounts of other active ingredients may also be varied Within the limits given, supra, while using identical compounding procedures.
The invention also includes the administration of the materials of the invention, said method comprising administering to the host about 1-5 parts 4:7-phenanthroline-5:6-quinone per -6 parts 5-chloro-8-hydroxy-7- iodoquinoline (preferably 1 part 4:7-phenanthroline-5z6- quinone per 10 parts 5-chloro-8-hydroxy-7-iodoquinoline) and an effective amount of an antibiotic (e.g., a penicillin, a tetracycline, a kanamycin, a neomycin, etc.) in an inert pharmaceutical carrier.
This invention may be variously otherwise embodied within the scope of the appended claims.
What is claimed is:
1. A pharmaceutical composition comprising about 1-5 mg. 4:7-phenanthroline-5:6-quinone and an efiective amount of an antibiotic selected from the group consisting of a penicillin, a tetracycline, bacitracin, carbomycin, cycloserine, erythromycin, chloramphenicol, kanamycin, neomycin, oleandornycin, spiramycin per 10-6 mg. 5- chloro-8-hydroxy-7-iodoquinoline and an inert pharmaceutical carrier.
2. A pharmaceutical composition comprising about 1-5 mg. 4:7-phenanthroline-5:6-quinone and about 1-1.5 million units of a penicillin per 10-6 mg. S-chloro-S-hydroxy-7-iodoquinoline, and an inert pharmaceutical carrier.
3. A pharmaceutical composition comprising about 1-5 mg. 4:7-phenanthroline-5:6-quinone and about 1-1.5 grams of a tetracycline per 10-6 mg. 5-chloro-8-hydroxy- 7-iodoquinoline, and an inert pharmaceutical carrier.
4. A pharmaceutical composition comprising about 1-5 mg. 4:7-phenanthroline-5:6-quinone and about 1-1.5 grams of an erythromycin per 10-6 mg. S-chloro-S-hydroxy-7-iodoquinoline, and an inert pharmaceutical carrier.
5. A pharmaceutical composition comprising about 1-5 mg. 4:7-phenanthroline-5:6-quinone, about 1-2 mg. dimethyl (Z-hydroxyethyl)methylammonium bromide uphenyl-cyclohexaneglycolate and an effective amount of an antibiotic selected from the group consisting of a penicillin, a tetracycline, bactitracin, carbornycin, cycloserine, erythromycin, chloramphenicol, kanamycin, neomycin, oleandomycin, spiramycin per 10-6 mg. 5-chloro-8-hydroxy-7-iodoquinoline, and an inert pharmaceutical carrier.
6. A pharmaceutical composition comprising about 1-5 mg. 4:7-phenanthroline-5:6-quinone, about 1-2 mg.
dimethyl(2-hydroxyethyl)methylammonium bromide 0tphenyl-cyclohexaneglycolate and about 1-1.5 million units of a penicillin per lO-6 mg. S-chloro-8-hydroxy-7-iodoquinoline, and an inert pharmaceutical carrier.
7. A pharmaceutical composition comprising about l-5 mg. 4:7-phenanthroline-5:6-quinone, 1-2 mg. dimethyl Z-hy-droxyethyl methylammonium bromide ot-phenylcyclohexaneglycolate and about 1-1.5 grams or" a tetracycline per 10-6 mg. 5-chloro--8-hydroxy-7-iodoquinoline, and an inert pharmaceutical carrier.
8. A pharmaceutical composition comprising about 1-5 mg. 4:7-phenanthroline-5:6-quinone, about 1-2 mg. dimethyl(Z-hydroxyethyl)methylammonium bromide v.- phenyl-cyclohexaneglycolate and about 1-1.5 grams of an erythromycin per 10-6 mg. 5-chloro-8-hydroxy-7- iodoquinoline, and an inert pharmaceutical carrier.
9. A pharmaceutical composition comprising about 1 mg. 4:7-phenanthroline-5:6-quinone and an eliective amount of an antibiotic selected from the group consisting of a penicillin, a tetracycline, bacitracin, carbomycin, cycloserine, erythromycin, chioramphenicol, kanamycin, neomycin, oleandomycin, spiramycin per 10 mg. 5-chloro- 8-hy droxy-7-iodoquinoline, and an inert pharmaceutical carrier.
10. A pharmaceutical composition comprising about 1 mg. 4:7-phenanthroline-5:G-quinone and about 1-1.5 million units of a penicillin per 10 mg. 5-chloro-8-hydroxy-"f-iodoquinoline, and an inert pharmaceutical carrier.
11. A pharmaceutical composition comprising about 1 mg. 4:7-phenanthroline-5:6-quinone and about 11.5 grams of a tetracycline per 10 mg. S-chloro-S-hydroxy- 7-iodoquinoline, and an inert pharmaceutical carrier.
12. A pharmaceutical composition comprising about 1 mg. 4:7-phenanthroline-5:6-quinone and about 11.5 grams of an erythromycin per 10 mg. 5-chloro-8-hydroxy- 7-1odoquinoline, and an inert pharmaceutical carrier.
13. A pharmaceutical composition comprising about 1 mg. 4:7-phenanthroline-5:o-quinone, 1-2 mg. dirnethyl(Z-hydroxyethyl)methylammonium bromide ot-phenylcyclohexaneglycolate and an effective amount of an antibiotic selected from the group consisting of a penicillin, 21 tetracycline, bacitracin, carbomycin, cycloserine, erythromycin, chioramphenicol, kanamycin, neomycin, oleandomycln, spiramycin per 10 mg. 5-chloro-8-hydroxy-7- rodoqumoline, and an inert pharmaceutical carrier.
14. A pharmaceutical composition comprising about 1 mg. 4:7-phenanthroline-5:6-quinone, 1 mg. dimethyl(2- hydroxyethyl)methylammonium bromide ct-phenyl-cyclohexaneglycolate and about 1-1.5 million units of a penic1ll1 n per 10 mg. 5-chloro-8-hydroxy-7-iodoquinoline and an inert pharmaceutical carrier.
15. A pharmaceutical composition comprising about 1 mg. 4:7-phenanthroline-5:6-quinone, 1 mg. dimethyl (Z-hydroxyethyl)methylammonium bromide a-phenyl-cyclohexaneglycolate and about 11.5 grams of a tetracvclme per 10 mg. S-chloro-8-hydroxy-7-iodoquinoline, and an inert pharmaceutical carrier.
16. A pharmaceutical composition comprising about 1 mg. 4:7-phenanthroline-5:o-quinone and 1 mg. dimethyl(2-hydroxyethyl)methylammonium bromide ot-phenylcyclohexaneglycolate and about 1-1.5 grams of an erythromycin per 10 mg. 5-chloro-8-hydroxy-7-iodoquinoline, and an inert pharmaceutical carrier.
17. A process which comprises orally administering to a host, for combatting infections involving post antibiotic enteritis, a pharmaceutical composition comprising about 1-5 mg. 4:7-phenanthroline-5:6-quinone and an effective amount of an antibiotic selected from the group consisting of a penicillin, a tetracycline, bacitracin, carbomycin, cycioserine, erythromycin, chloramphenicol, kanamycin, neomycin, oleandomycin, spiramycin per 10-6 mg. S-chloro-8-hydroxy-7-iodoquinoline, and an inert pharmaceutical carrier.
18. A process which comprises orally administering to a host, for combatting infections involving post antibiotic enteritis, a pharmaceutical composition comprising about 1-5 mg. 4:7-phenanthroline-5:6-quinone, about 1-2 mg. dimethyl(Z-hydroxyethyl)methylammonium bromide aphenyl-cyclohexaneglycolate and an effective amount of an antibiotic selected from the group consisting of a penicillin, a tetracycline, bacitracin, carbomycin, cycloserine, erythromycin, chloramphenicol, kanamycin, neomycin, oleandomycin, spiramycin per 10-6 mg. 5-chloro-8-hydroxy-7-iodoquinoline, and an inert pharmaceutical carrier.
19. A process Which comprises orally administering to a host, for combatting infections involving post antibiotic enteritis, a pharmaceutical composition comprising about 1-5 mg. 4:7-phenanthroline-5:6-quinone and about 1-1.5 grams of a tetracycline per 10-6 mg. S-chloro-S-hydroxy- 7-iodoquinoline, and an inert pharmaceutical carrier.
Wilcox June 7, 1949 Druey et al Apr. 12, 1955 OTHER REFERENCES Turell: J.A.M.A., vol. 156, No. 3, pp. 217-220.
Brown et al.: Science, May 29, 1953, vol. 117, pp. 609-10.
Blank: A.M.A., Arch. of Dermat, vol. 75, No. 2, 1957, pp. 184-192.
Quinn: Antibiotics and Chemotherapy, vol. 10, No. 2, pp. 95-100.
Chem. Abs. I, v01. 44, 5910 (Ciba), 1950.
Plummer: Chem. Abs. II, vol. 47, 11519, 1953.
Merck Index, 6th Ed., 1952, p. 530.
Entero-vioform. PDR, 1960, p. 655.
Claims (1)
1. A PHARMACEUTICAL COMPOSITION COMPRISING ABOUT 1-5 MG. 4:7-PHENATHROLINE-5:6-QUINONE AND AN EFFECTIVE AMOUNT OF AN ANTIBIOTIC SELECTED FROM THE GROUP CONSISTING OF A PENICILLIN, A TETRACYCLINE, BACITRACIN, CARBOMYCIN, CYCLOSERINE, ERYTHROMYCIN, CHLORAMPHEICOL, KANAMYCIN, NEOMYCIN, OLEANDOMYCIN, SPIRAMYCIN PER 10-6 MG. 5CHLORO-8-HYDROXY-7-IODOQUINOLINE AND AN INERT PHARMACEUTICAL CARRIER.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79583A US3174899A (en) | 1960-12-30 | 1960-12-30 | Composition for the management of post antibiotic enteritis |
| BE612166A BE612166A (en) | 1960-12-30 | 1961-12-29 | Pharmaceutical composition comprising, inter alia, an antibiotic and a phenanthroline-5, 6-quinone |
| FR883381A FR1715M (en) | 1960-12-30 | 1961-12-29 | Therapeutic composition. |
| GB46761/61A GB951992A (en) | 1960-12-30 | 1961-12-29 | Pharmaceutical preparations comprising antibiotics and phenanthroline quinones |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79583A US3174899A (en) | 1960-12-30 | 1960-12-30 | Composition for the management of post antibiotic enteritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US3174899A true US3174899A (en) | 1965-03-23 |
Family
ID=22151455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US79583A Expired - Lifetime US3174899A (en) | 1960-12-30 | 1960-12-30 | Composition for the management of post antibiotic enteritis |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US3174899A (en) |
| BE (1) | BE612166A (en) |
| FR (1) | FR1715M (en) |
| GB (1) | GB951992A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3926921A (en) * | 1973-03-27 | 1975-12-16 | Crinos Industria Farmaco | Pharmaceutical compositions comprising mixed salts of sulfoglycopeptides with metal and organic bases |
| US4997823A (en) * | 1986-02-18 | 1991-03-05 | Syntex (U.S.A.) Inc. | Anti-infective injectable formulations |
| CN103263267A (en) * | 2013-05-02 | 2013-08-28 | 中国人民公安大学 | Ethanol solution method for quickly displaying metal reserved marks on skin surfaces of human bodies |
| CN111848663A (en) * | 2020-08-27 | 2020-10-30 | 西南大学 | Non-metal organic complex salt of phenanthroline and phenanthroline derivative, and preparation method and application thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0959888B1 (en) * | 1996-08-13 | 2001-09-05 | P.N. Gerolymatos S.A. | Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease |
| US5994323A (en) * | 1997-12-31 | 1999-11-30 | P.N. Gerolymatos S.A. | Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2472640A (en) * | 1945-02-10 | 1949-06-07 | Sharp & Dohme Inc | Clear aqueous solutions of tyrothricin |
| US2706197A (en) * | 1955-04-12 | Phenanthroline-quinones and process of |
-
1960
- 1960-12-30 US US79583A patent/US3174899A/en not_active Expired - Lifetime
-
1961
- 1961-12-29 BE BE612166A patent/BE612166A/en unknown
- 1961-12-29 GB GB46761/61A patent/GB951992A/en not_active Expired
- 1961-12-29 FR FR883381A patent/FR1715M/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2706197A (en) * | 1955-04-12 | Phenanthroline-quinones and process of | ||
| US2472640A (en) * | 1945-02-10 | 1949-06-07 | Sharp & Dohme Inc | Clear aqueous solutions of tyrothricin |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3926921A (en) * | 1973-03-27 | 1975-12-16 | Crinos Industria Farmaco | Pharmaceutical compositions comprising mixed salts of sulfoglycopeptides with metal and organic bases |
| US4997823A (en) * | 1986-02-18 | 1991-03-05 | Syntex (U.S.A.) Inc. | Anti-infective injectable formulations |
| CN103263267A (en) * | 2013-05-02 | 2013-08-28 | 中国人民公安大学 | Ethanol solution method for quickly displaying metal reserved marks on skin surfaces of human bodies |
| CN111848663A (en) * | 2020-08-27 | 2020-10-30 | 西南大学 | Non-metal organic complex salt of phenanthroline and phenanthroline derivative, and preparation method and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| FR1715M (en) | 1963-02-25 |
| GB951992A (en) | 1964-03-11 |
| BE612166A (en) | 1962-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4394377A (en) | Ruminant animal performance by co-administering choline and propionate enchancers | |
| US3081233A (en) | Enteric-coated pilules | |
| DD216163A5 (en) | METHOD OF PREPARING AN ORAL TREATABLE CEFACLOR PREPARATION WITH DELAYED ACTIVE SUBSTANCE | |
| US4808412A (en) | Rumen-stable compositions | |
| US3562806A (en) | Rumen stable medicament and/or nutrient compositions | |
| JPS641442B2 (en) | ||
| US4066754A (en) | Slow release bolus | |
| US3174899A (en) | Composition for the management of post antibiotic enteritis | |
| US4366168A (en) | Anticoccidial combinations | |
| WO1999000122A1 (en) | Method for reducing body weight | |
| US3949077A (en) | Synergistic antibiotic compositions | |
| PL221310B1 (en) | Treatment and prophylaxis of diseases and infections of pigs and poultry with aivlosin | |
| US3991209A (en) | Halomethanesulfonamides for eradicating internal parasites | |
| JPS59108798A (en) | Manufacture of antibiotic a 204 i derivative | |
| US5872128A (en) | Stabilized composition of ticlopidine hydrochloride | |
| US3178343A (en) | Pharmaceutical compositions and method of using same | |
| JPS6114124B2 (en) | ||
| US3729563A (en) | Method of treating movement disorders | |
| US3642987A (en) | Lincomycin and tetracycline compositions | |
| US4291053A (en) | Agent to be administered orally to domestic animals without cellulose digestion in the rumen | |
| US4123553A (en) | Anthelmintics effective against liver flukes | |
| NZ512973A (en) | Methods for reducing mortality rates in poultry | |
| CA1143658A (en) | Skeletal muscle relaxant | |
| US3867544A (en) | 4-Nitro-4{40 -(trifluoromethyl) carbanilide employed in animal husbandry | |
| US3192108A (en) | Anthelmintic compositions and method of using same |